Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Common Equity: 2022-2025

Historic Common Equity for Day One Biopharmaceuticals (DAWN) over the last 4 years, with Sep 2025 value amounting to $450.9 million.

  • Day One Biopharmaceuticals' Common Equity fell 18.83% to $450.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $450.9 million, marking a year-over-year decrease of 18.83%. This contributed to the annual value of $502.8 million for FY2024, which is 45.08% up from last year.
  • Day One Biopharmaceuticals' Common Equity amounted to $450.9 million in Q3 2025, which was down 2.16% from $460.8 million recorded in Q2 2025.
  • In the past 5 years, Day One Biopharmaceuticals' Common Equity registered a high of $555.5 million during Q3 2024, and its lowest value of $259.6 million during Q1 2022.
  • Over the past 3 years, Day One Biopharmaceuticals' median Common Equity value was $426.1 million (recorded in 2023), while the average stood at $410.5 million.
  • Per our database at Business Quant, Day One Biopharmaceuticals' Common Equity declined by 28.01% in 2024 and then spiked by 61.56% in 2025.
  • Quarterly analysis of 4 years shows Day One Biopharmaceuticals' Common Equity stood at $332.0 million in 2022, then rose by 4.37% to $346.5 million in 2023, then spiked by 45.08% to $502.8 million in 2024, then declined by 18.83% to $450.9 million in 2025.
  • Its last three reported values are $450.9 million in Q3 2025, $460.8 million for Q2 2025, and $479.5 million during Q1 2025.